Canavero Isabella, Micieli Giuseppe, Paciaroni Maurizio
1 Department of Emergency Neurology, IRCCS National Neurological Institute "Casimiro Mondino," Pavia, Italy.
2 Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, "Santa Maria della Misericordia" Hospital, Perugia, Italy.
Clin Appl Thromb Hemost. 2018 Apr;24(3):396-404. doi: 10.1177/1076029617720068. Epub 2017 Sep 15.
Direct oral anticoagulants (DOACs) are valid alternative options to vitamin K antagonists due to their limited interactions with drugs or food and the fact that they do not require regular coagulation monitoring. To this regard, recent practice guidelines recommend that DOACs should be considered as first-line anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). This review (1) outlines current international guidelines for the management of DOACs to prevent stroke in patients with NVAF, (2) outlines indications for elderly patients as well as specific settings including acute coronary syndromes and intracranial hemorrhage, and (3) offers a practical guide for the use of DOACs in neurological settings.
直接口服抗凝剂(DOACs)是维生素K拮抗剂的有效替代选择,因为它们与药物或食物的相互作用有限,且无需定期进行凝血监测。鉴于此,近期的实践指南建议,DOACs应被视为非瓣膜性心房颤动(NVAF)患者预防中风的一线抗凝治疗药物。本综述(1)概述了目前关于使用DOACs预防NVAF患者中风的国际管理指南,(2)概述了老年患者以及包括急性冠脉综合征和颅内出血在内的特定情况的适应证,(3)提供了在神经科环境中使用DOACs的实用指南。